-
Sector Analysis
Automotive Steering Systems Market Trends, Sector Overview and Forecast to 2028
Automotive Steering Systems Market Report Overview The steering systems market size was 91 million units in 2023. The market will grow at a CAGR of more than 1% during 2023-2028. Continuous advancements in technology, such as improvements in electric power steering (EPS), sensors, and control algorithms drive the innovation of steering systems. In 2023, Asia-Pacific accounted for a significant share of the automotive steering systems market. Automotive Steering Systems Market Outlook, 2023-2028 (Million Units) Buy the Full Report for More...
-
Company Insights
Innovation and Patenting activity of CD Projekt RED SA Q1 2024
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of CD Projekt RED SA Q1 2024". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CD-388 in Seasonal Influenza
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CD-388 in Seasonal Influenza report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.CD-388 in Seasonal Influenza Drug Details:CD-388 is under development for the treatment and...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CD-388 in Pandemic Influenza
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CD-388 in Pandemic Influenza report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.CD-388 in Pandemic InfluenzaDrug Details:CD-388 is under development for the treatment and prevention...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CD-388 in Influenzavirus B Infections
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CD-388 in Influenzavirus B Infections report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.CD-388 in Influenzavirus B Infections Drug Details:CD-388 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Furestem-CD in Crohn’s Disease (Regional Enteritis)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Furestem-CD in Crohn's Disease (Regional Enteritis) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Furestem-CD in Crohn's Disease (Regional Enteritis) Drug Details: Furestem-CD...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Regorafenib in Soft Tissue Sarcoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Regorafenib in Soft Tissue Sarcoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Regorafenib in Soft Tissue Sarcoma Drug Details: Regorafenib (BAY 73-4506,...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – LuAG-13909 in Congenital Adrenal Hyperplasia (Adrenogenital Syndrome)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. LuAG-13909 in Congenital Adrenal Hyperplasia (Adrenogenital Syndrome) Drug Details: LuAG-13909 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AVA-001 in Non-Hodgkin Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - AVA-001 in Non-Hodgkin Lymphoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. AVA-001 in Non-Hodgkin Lymphoma Drug Details: AVA-001 is under development for...